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Abstract: Leptin is an endocrine hormone that has a critical role in body weight homoeostasis and
mediates its effects via the leptin receptor (LEPR). Common polymorphisms in the genes coding
leptin receptors have been associated with metabolic abnormalities. We assessed the association of
28 LEPR polymorphisms with body mass index (BMI) and their relationship with obesity-related
phenotypes, inflammation and cardiovascular disease risk biomarkers. A multicentre case-control
study was conducted in 522 children (286 with obesity and 236 with normal-BMI). All anthropometric,
metabolic factors and biomarkers were higher in children with obesity except apolipoprotein
(Apo)-AI, cholesterol, high-density lipoprotein cholesterol (HDL-c), and adiponectin, which were
lower in the obesity group; and glucose, low-density lipoprotein cholesterol (LDL-c), and matrix
metalloproteinase-9 that did not differ between groups. We identified the associations between
rs11208659, rs11804091, rs10157275, rs9436303 and rs1627238, and BMI in the whole population,
as well as the association of rs11804091, rs10157275, and rs1327118 with BMI in the female group,
although only the rs11804091 remained associated after Bonferroni correction (p = 0.038). This single
nucleotide polymorphisms (SNP) was also associated with insulin (p = 0.004), homeostasis model
assessment for insulin resistance (HOMA-IR) (p = 0.006), quantitative insulin sensitivity check index
(QUICKI) (p = 0.005) and adiponectin (p = 0.046) after adjusting for age, Tanner stage and BMI. Our
results show a sex-specific association between the rs11804091 and obesity suggesting an influence of
this SNP on insulin resistance.
Keywords: LEPR gene; genetic polymorphism; obesity; child; insulin resistance
1. Introduction
Paediatric obesity is a complex condition originated from both environmental and genetic
factors [1]. It has become a worldwide public health concern as it has dramatically increased over
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the past three decades [2,3]. Genetic association studies have provided insights into the genetics of
early-onset obesity, identifying strongly associated genes with large phenotypic effects such as the
leptin (LEP) or leptin receptor (LEPR) genes [4]. Leptin is an endocrine hormone mainly produced by
the adipose tissue, which has a critical role in body weight homeostasis [5]; its circulating levels are
correlated with the amount of body fat and reflect the nutritional status [6]. Leptin mediates its effects
via the leptin receptor, which is a member of the Class I cytokine receptor family and consists of an
extracellular ligand-binding transmembrane domain and a cytoplasmic signalling domain [7]. Once in
the bloodstream, leptin reaches the brain by crossing the blood–brain barrier (BBB), and binds to its
receptor in the hypothalamus arcuate nucleus; there, the activation of the receptor inhibits the action
of orexigenic peptides and stimulates anorectic neuropeptides, ensuing in the control of appetite and
food intake [8]. Leptin also participates in the regulation of glucose homeostasis and insulin sensitivity,
since these two hormones exert opposite effects and regulate each other in such a way that leptin
inhibits insulin, and insulin stimulates leptin synthesis and secretion [9].
Leptin resistance defines a state of obesity where hyperleptinemia or diminished responsiveness
to this hormone is observed. The lack of response to leptin due to the development of resistance may
disturb central and peripheral actions of this hormone. Although some proposals have been made
such as failure of leptin crossing the BBB, inhibition of the leptin signalling cascade, or a decrease in the
expression of leptin receptors, to date the mechanisms underlying leptin resistance remain unclear [10].
In both the LEP and LEPR genes, homozygous mutations have been described that derive in
extreme obesity [11–13]. In addition, a variety of single nucleotide polymorphisms (SNPs) in different
loci have been associated with circulating leptin levels and obesity [14–16]. In the LEPR gene, different
SNPs conferring increased susceptibility to common forms of obesity have been identified in adults [16],
families [16–23] and children [24–30] with different ethnic backgrounds. In addition, other variants
such as Gln223Arg (rs1137101) in this gene have been associated with type 2 diabetes [31]. However,
although the common forms of obesity are a major public health problem and the impairment of the
action of leptin and its receptor are implicated in the onset of obesity, few studies have investigated
the contribution of LEPR genetic variants to the susceptibility to childhood obesity also focusing on
their association with circulating biomarkers.
With all this in mind, the present study was undertaken with the aim of elucidating the possible
association regarding LEPR variants in the setting or development of obesity in children. For this, we
examined the association of 28 LEPR polymorphisms with body mass index (BMI) and analysed their
relationship with biomarkers of insulin resistance, inflammation and cardiovascular disease (CVD)
risk in Spanish children.
2. Results
2.1. General Characteristics of the Population
Table 1 shows the anthropometric, clinical and metabolic characteristics of the studied groups,
as previously published [32]. As expected, weight, height, BMI, BMI z-Score (z-BMI) and waist
circumference (WC) were significantly higher in children with obesity compared to children with
normal-BMI. Systolic and diastolic blood pressure (BP), as well as plasma triacylglycerols (TAG),
apolipoprotein (Apo)-B, insulin, and homeostatic model assessment of insulin resistance (HOMA-IR),
were higher in children with obesity, whereas the quantitative insulin sensitivity check index
(QUICKI), plasma total cholesterol, high-density lipoprotein-cholesterol (HDL-c) and Apo-AI were
lower in this group when compared with normal-weight children. Fasting plasma glucose and
low-density lipoprotein-cholesterol (LDL-c) concentrations showed no differences between groups.
The concentrations of alanine transaminase and γ-glutamyl transpeptidase were higher in the obesity
group, while that of aspartate transaminase was lower.
Plasma leptin concentration was significantly higher in subjects with obesity than in the
normal-BMI subjects, whereas adiponectin was lower. Inflammation and most of the CVD risk
Int. J. Mol. Sci. 2017, 18, 1690 3 of 14
biomarkers differed between groups. C-reactive protein (CRP), interleukin (IL) 6, IL-8, and tumour
necrosis factor alpha (TNF-α) were higher in the obesity group compared with the normal-BMI group.
Likewise, plasma soluble intracellular adhesion molecule-1 (sICAM-1), soluble endothelial selectin
(sE-selectin), myeloperoxidase (MPO) and active and total plasminogen activator inhibitor (PAI-1) were
higher in children with obesity, whereas matrix metalloproteinase-9 (MMP-9) showed no differences
between groups.




Sex (M/F) 133/103 146/140 0.252




Weight (kg) 32.9 ± 0.7 55.9 ± 1.0 <0.001
Height (m) 1.37 ± 0.01 1.41 ± 0.01 0.002
BMI (kg/m2) 17.14 ± 0.13 27.59 ± 0.24 <0.001
BMI z-Score −0.17 ± 0.04 3.50 ± 0.08 <0.001
Waist circumference (cm) 60.3 ± 0.5 84.0 ± 0.9 <0.001
Clinical and Metabolic Biomarkers
Systolic BP (mm Hg) 98 ± 1 111 ± 1 <0.001
Diastolic BP (mm Hg) 60 ± 1 69 ± 1 <0.001
Glucose (mg/dL) 84 ± 1 85 ± 1 0.816
Insulin (mU/L) 5.89 ± 0.23 11.53 ± 0.52 <0.001
HOMA-IR 1.26 ± 0.05 2.45 ± 0.12 <0.001
QUICKI 0.383 ± 0.003 0.347 ± 0.002 <0.001
Triacylglycerols (mg/dL) 55 ± 1 75 ± 2 <0.001
Apo-AI (mg/dL) 149 ± 2 132 ± 2 <0.001
Apo-B (mg/dL) 67 ± 1 71 ± 1 0.006
Cholesterol (mg/dL) 171 ± 2 165 ± 2 0.024
HDL-c (mg/dL) 64 ± 1 51 ± 1 <0.001
LDL-c (mg/dL) 94 ± 2 97 ± 2 0.136
AST (U/L) 23.70 ± 0.48 21.23 ± 0.40 <0.001
ALT (U/L) 16.80 ± 0.57 20.88 ± 0.51 <0.001
GGT (U/L) 8.44 ± 0.27 10.90 ± 0.30 <0.001
Adiponectin (mg/L) 28.23 ± 0.77 22.53 ± 0.66 <0.001
Resistin (µg/L) 9.67 ± 0.34 11.77 ± 0.35 <0.001
Leptin (µg/L) 4.30 ± 0.26 23.15 ± 0.87 <0.001
Inflammation Biomarkers
C-reactive protein
(mg/L) 0.97 ± 0.23 3.44 ± 0.25 <0.001
Interleukin 6 (ng/L) 4.55 ± 0.54 7.03 ± 0.76 0.008
Interleukin 8 (ng/L) 1.57 ± 0.11 2.17 ± 0.15 0.002
TNF-α (ng/L) 3.04 ± 0.11 4.00 ± 0.13 <0.001
Cardiovascular Disease Risk Biomarkers
MMP-9 (µg/L) 79.72 ± 3.17 87.98 ± 3.92 0.714
MPO (µg/L) 13.18 ± 1.18 21.70 ±1.73 <0.001
sE selectin (µg/L) 22.91 ± 0.77 31.36 ± 1.06 <0.001
sICAM-1 (mg/L) 0.153 ± 0.004 0.174 ± 0.005 <0.001
Active PAI-1 (µg/L) 5.07 ± 0.26 11.92 ± 0.58 <0.001
Total PAI-1 (µg/L) 18.82 ± 0.85 27.11 ± 1.12 <0.001
Mean ± standard error of the mean (SEM). M: male; F: female; y: year; BMI: body mass index; BP: blood pressure;
HOMA-IR: homeostasis model assessment for insulin resistance; QUICKI: quantitative insulin sensitivity check
index; Apo: apolipoprotein; HDL-c: high-density lipoprotein cholesterol; LDL-c: low-density lipoprotein cholesterol;
ALT: alanine transaminase; AST: aspartate transaminase; GGT: gamma-glutamyl transpeptidase; TNF-α: tumour
necrosis factor alpha; MMP-9: metalloproteinase-9; MPO: myeloperoxidase; sICAM-1: soluble intracellular adhesion
molecule-1, PAI-1: plasminogen activator inhibitor.
Int. J. Mol. Sci. 2017, 18, 1690 4 of 14
2.2. Association of LEPR SNPs with Obesity
Among the 28 analysed SNPs, only the rs11208659, rs11804091, rs10157275, rs9436303, and
rs1627238 were significantly associated with obesity in children, after age, sex and Tanner stage
adjustment under an additive model (Table 2). However, none of the SNPs remained significantly
associated after Bonferroni correction. When we performed the analysis separately by sex, we observed
that rs11804091 and rs10157275, and additionally, rs1327118, were associated with BMI only in the
female group, although only rs11804091 remained statistically significant after Bonferroni correction
(OR = 2.73 for allelic effect, 95% CI: 1.47–5.08, p = 0.038). No association was observed between these
SNPs and obesity in the male group; only rs11208659 showed a negative association with obesity
in males that was lost after Bonferroni correction (Table 3). However, the previously described in
adults SNPs, rs1137101, rs1137100, and rs8179183, were not associated with BMI in our population.
Additionally, haplotype analyses showed that none of the significantly associated SNPs were in linkage
disequilibrium (LD) with the three mentioned above, either considering the whole population or when
analyses were performed separately by sex (Figures S1–S3).
Since our population came from two different cities of Spain, we performed a meta-analysis to
avoid population stratification biases or a genotyping batch effect. The results of this analysis (p values
of Q Cochrane: (rs11208659, Q = 0.997; rs11804091, Q = 0.228; rs10157275, Q = 0.304; rs9436303,
Q = 0.166; and rs1627238, Q = 0.887) indicates little detectable heterogeneity for the two considered
populations of the study.
To investigate the potential functional role of these variants, different web-based tools designed
for in silico prediction of SNP function were queried using the SNP IDs, including the FuncPRED tool
of the National Institutes of Health [33], RegulomeDB [34], MirSNP [35], and RegSNP [36]. The search
showed no determinant effect of the significantly obesity associated SNPs on the binding of known
transcription factors or microRNAs. Moreover, other variants found to be in LD with the associated
SNPs, including one missense polymorphism, were not predicted to influence the function of the
protein or the binding of transcription factors or microRNAs to the LEPR gene.
2.3. Association of SNP rs11804091 with Obesity-Related Traits
Table 4 shows the association of rs11804091 in the female population with anthropometric, clinical,
inflammation and CVD risk markers adjusted by age and Tanner stage. This SNP was significantly
positively associated with weight, z-BMI, systolic BP, insulin, HOMA-IR, Apo-AI, leptin, and TNF-α;
and significantly negatively associated with height, QUICKI and adiponectin. This negative association
with height could be due to the lower mean age of the GG genotype group (7.9 years). After an
additional adjustment for BMI, insulin, HOMA-IR, QUICKI and adiponectin remained significantly
associated ((β = 0.09 mU/L; 95% CI: 0.03, 0.15; p = 0.004), (β = 0.09; 95% CI: 0.03, 0.15; p = 0.006),
(β = −0.019 mg/L; 95% CI: −0.028, −0.009; p = 0.005) and (β = −3.09 mg/L; 95% CI: −6.11, −0.07;
p = 0.046), respectively).
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OR (95% CI) p p a
11 12 22 11 12 22 Case Control
rs11208659 Intron T/C 240 44 2 173 61 2 C 0.084 0.138 0.54 (0.35–0.81) 0.003 0.076
rs11804091 Intron A/G 193 76 8 181 46 2 G 0.166 0.109 1.64 (1.13–2.39) 0.010 0.251
rs10157275 Intron C/T 195 83 8 184 46 6 T 0.173 0.123 1.53 (1.08–2.18) 0.017 0.444
rs9436303 Intron A/G 162 100 24 152 73 11 G 0.259 0.201 1.36 (1.02–1.81) 0.036 0.926
rs1627238 Intron C/T 186 87 13 167 60 5 T 0.198 0.151 1.40 (1.01–1.94) 0.046 1
rs17412175 Intron T/A 82 146 58 57 120 58 A 0.458 0.502 0.82 (0.64–1.06) 0.133 1
rs9436739 Intron T/A 231 53 2 178 56 2 A 0.100 0.127 0.74 (0.50–1.10) 0.135 1
rs1137101 Gln223Arg A/G 85 135 65 76 117 41 G 0.465 0.425 1.16 (0.91–1.48) 0.243 1
rs6673591 Intron A/G 83 129 74 55 121 60 G 0.484 0.511 0.89 (0.70–1.13) 0.325 1
rs17412723 Intron A/G 71 155 60 58 114 62 G 0.481 0.509 0.88 (0.68–1.14) 0.329 1
rs6697315 Intron T/C 126 125 35 92 113 30 C 0.341 0.368 0.88 (0.68–1.14) 0.329 1
rs6704167 Intron A/T 92 138 56 68 114 52 T 0.437 0.466 0.88 (0.69–1.13) 0.330 1
rs8179183 Lys656Asn G/C 195 82 9 153 72 10 C 0.175 0.196 0.87 (0.63–1.19) 0.379 1
rs1327118 PRO G/C 73 143 59 62 121 42 C 0.475 0.456 1.10 (0.85–1.43) 0.472 1
rs1137100 Lys109Arg A/G 155 112 19 133 89 14 G 0.262 0.248 1.09 (0.82–1.45) 0.552 1
rs3806318 PRO A/G 158 104 24 116 101 16 G 0.266 0.285 0.92 (0.70–1.21) 0.562 1
rs970468 Intron T/G 123 135 28 96 113 26 G 0.334 0.351 0.93 (0.71–1.22) 0.588 1
rs3790429 Intron A/T 187 93 5 161 64 8 T 0.181 0.172 1.09 (0.78–1.51) 0.630 1
rs9436740 Intron A/T 143 115 24 119 89 26 T 0.289 0.301 0.95 (0.73–1.24) 0.704 1
rs1475397 Intron C/T 149 118 19 122 95 19 T 0.273 0.282 0.95 (0.72–1.25) 0.712 1
rs11585329 Intron T/G 215 64 7 171 61 4 T 0.136 0.146 0.94 (0.66–1.33) 0.718 1
rs4655802 Intron A/G 92 133 55 74 111 41 G 0.434 0.427 1.03 (0.80–1.32) 0.828 1
rs6678033 Intron G/A 107 136 43 91 111 34 A 0.388 0.379 1.03 (0.80–1.33) 0.829 1
rs6672331 Intron G/C 273 13 0 224 12 0 C 0.023 0.025 0.94 (0.42–2.12) 0.886 1
rs1137099 Thr85Ala A/ 286 0 0 236 0 0 0 0 - - -
rs13306526 Ile503Val A/ 286 0 0 236 0 0 0 0 - - -
CI: confidence interval; OR: odds ratio; PRO: promoter. OR adjusted for age, sex and Tanner stage under the additive model. a p values after Bonferroni correction. The bold is the statistic
significance for the rows where p is lower than 0.05.
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OR (95% CI) p p a
11 12 22 11 12 22 Case Control
Females
rs11208659 T/C 113 26 1 72 3 1 C 0.100 0.155 0.56 (0.31–1.00) 0.050 1
rs11804091 A/G 87 42 4 82 19 0 G 0.188 0.094 2.73 (1.47–5.08) 0.001 0.038
rs10157275 C/T 99 37 4 84 17 2 T 0.161 0.102 1.77 (1.01–3.12) 0.045 1
rs9436303 A/G 77 52 11 68 30 5 G 0.264 0.194 1.49 (0.95–2.32) 0.080 1
rs1627238 C/T 93 41 6 75 23 2 T 0.189 0.135 1.59 (0.95–2.32) 0.079 1
rs1327118 G/C 32 73 30 29 54 12 C 0.493 0.411 1.53 (1.01–2.32) 0.048 1
Males
rs11208659 T/C 127 18 1 101 31 1 C 0.068 0.124 0.50 (0.27–0.92) 0.026 0.681
rs11804091 A/G 106 34 4 99 27 2 G 0.146 0.121 1.23 (0.76–2.02) 0.837 1
rs10157275 C/T 96 46 4 100 29 4 T 0.185 0.139 1.40 (0.89–2.21) 0.147 1
rs9436303 A/G 85 48 13 84 43 6 G 0.253 0.207 1.28 (0.87–1.87) 0.218 1
rs1627238 C/T 93 46 7 92 37 3 T 0.206 0.163 1.33 (0.86–2.04) 0.202 1
rs1327118 G/C 41 70 29 33 67 30 C 0.457 0.489 0.88(0.63–1.24) 0.465 1
CI: confidence interval; OR: odds ratio. OR adjusted for age and Tanner stage under the additive model. a p values after Bonferroni correction. The bold is the statistic significance for the
rows where p is lower than 0.05.
Table 4. Association of rs11804091 with anthropometric, clinical, inflammation and CVD risk biomarkers in girls.
Biomarkers AA AG GG β (95% CI) p p a
n 169 61 4
Anthropometry
Height (m) 1.37 ± 0.01 1.41 ± 0.02 1.35 ± 0.05 −0.014 (−0.025, −0.004) 0.010 –
Weight (kg) 43.1 ± 1.4 49.9 ± 2.5 50.5 ± 7.9 6.1 (2.6, 9.6) 0.001 –
BMI (kg/m2) 22.44 ± 0.47 24.41 ± 0.78 27.33 ± 2.15 2.20 (0.70, 3.70) 0.004 –
BMI z-Score 1.57 ± 0.15 2.08 ± 0.23 3.51 ± 0.45 0.70 (0.22, 1.18) 0.004 –
Waist circumference (cm) 71.56 ± 1.31 76.07 ± 2.14 80.75 ± 2.39 5.46 (2.62, 9.59) 0.055 0.667
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Table 4. Cont.
Biomarkers AA AG GG β (95% CI) p p a
Clinical and Metabolic Biomarkers
Systolic BP (mm Hg) 104 ± 1 108 ± 2 120 ± 3 5.56 (1.97, 9.14) 0.003 0.092
Diastolic BP (mm Hg) 65 ± 1 66 ± 1 73 ± 6 2.49 (−0.51, 5.49) 0.105 0.569
Glucose (mg/dL) 84 ± 1 85 ± 1 79 ± 2 −0.08 (−1.94, 1.78) 0.934 0.989
Insulin (mU/L) 9.11 ± 0.60 12.64 ± 1.15 10.95 ± 3.25 0.14 (0.07, 0.21) 0.0001 0.004
HOMA-IR 1.91 ± 0.13 2.70 ± 0.28 2.17 ± 0.69 0.14 (0.07, 0.22) 0.0002 0.006
QUICKI 0.367 ± 0.003 0.342 ± 0.004 0.349 ± 0.014 −0.019 (−0.028, −0.009) 0.0001 0.005
Triacylglycerols (mg/dL) 69 ± 3 70 ± 4 130 ± 32 8.50 (−0.17, 17.17) 0.056 0.376
Apo-AI (mg/dL) 139 ± 2 131 ± 3 122 ± 9 −8.19 (−15.01, −1.37) 0.019 0.129
Cholesterol (mg/dL) 168 ± 2 169 ± 4 180 ± 14 2.01 (−5.11, 0.55) 0.604 0.334
HDL-c (mg/dL) 55 ± 2 52 ± 2 62 ± 17 −1.83 (−5.68, 2.01) 0.350 0.649
Adiponectin (mg/L) 26.67 ± 0.95 20.96 ± 1.48 23.33 ± 2.30 −4.77 (−7.94, −1.60) 0.004 0.046
Leptin (µg/L) 13.66 ± 1.03 19.01 ± 2.13 19.81 ± 3.69 5.10 (0.04, 1.06) 0.006 0.314
Inflammation Biomarkers
C-reactive protein (mg/L) 2.29 ± 0.41 3.42 ± 0.52 1.65 ± 0.61 0.84 (−0.45, 2.13) 0.202 0.633
IL-6 (ng/L) 6.03 ± 0.89 5.38 ± 0.99 18.16 ± 9.07 0.92 (−1.91, 3.77) 0.522 0.737
IL-8 (ng/L) 1.80 ± 0.13 1.79 ± 0.25 3.63± 1.51 0.21 (−0.26, 0.69) 0.381 0.637
TNF-α (ng/L) 3.26 ± 0.15 3.84 ± 0.31 4.02 ± 0.94 0.55 (0.04, 1.06) 0.035 0.090
Cardiovascular Disease Risk Biomarkers
MMP-9 (µg/L) 84.18 ± 4.44 78.82 ± 6.59 75.67 ± 13.56 −5.36 (−19.92, 9.11) 0.494 0.489
MPO (µg/L) 17.27 ± 1.47 21.59 ± 4.28 22.05 ± 7.14 3.47 (−2.63, 9.58) 0.266 0.572
sE-Selectin (µg/L) 26.78 ± 1.22 29.67 ± 2.44 21.99 ± 5.74 2.54 (−1.89, 6.97) 0.263 0.518
sICAM-1 (mg/L) 0.164 ± 0.005 0.160 ± 0.009 0.218 ± 0.047 0.002 (−0.016, 0.021) 0.766 0.889
Active PAI-1 (µg/L) 9.51 ± 0.69 9.63 ± 1.12 15.55 ± 6.81 0.89 (−1.47, 3.26) 0.461 0.441
Total PAI-1 (µg/L) 23.75 ± 1.29 23.56 ± 2.54 28.67 ± 9.17 0.62 (−3.98, 5.23) 0.713 0.707
CI: Confidence interval; BMI: body mass index; BP: blood pressure; HOMA-IR: homeostasis model assessment for insulin resistance; QUICKI: quantitative insulin sensitivity check
index; HDL-c: high-density lipoprotein cholesterol; IL: interleukin; TNF-α: tumour necrosis factor alpha; MMP-9: matrix metalloproteinase-9; MPO: myeloperoxidase; sICAM-1: soluble
intracellular adhesion molecule-1; sE-selectin: soluble endothelial selectin; PAI-1: plasminogen activator inhibitor. β Coefficients represent the change in absolute traits values of each
additional risk allele. General linear or logistic models were used to examine associations, p adjusted by age and Tanner stage, p a adjusted by age, Tanner stage, and BMI.
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3. Discussion
The main finding of our study was the sex-specific association between rs11804091 and obesity and
insulin resistance in girls. We show the association between this SNP and anthropometric, clinical and
metabolic obesity-related markers. Moreover, after adjusting for BMI, this SNP remained associated
positively with insulin and HOMA-IR, and negatively with QUICKI and adiponectin. Our results
suggest that the polymorphism rs11804091, or a flagged variant in LD with it, might have an effect on
leptin action with an impact on insulin signalling which does not depend entirely on adiposity.
Leptin and insulin are two body energy sensors that act in the hypothalamus through their
respective receptors regulating several peripheral functions. Both promote changes in the expression
of hypothalamic neuropeptides to regulate energy balance and glucose metabolism [37]. Two separate
studies have shown that the reintroduction of the leptin receptors in the hypothalamus of LEPR null
mice reduces obesity in different degrees and through different actions [38,39]. When LEPR were
reintroduced in the pro-opiomelanocortin (POMC) neurones, which usually express LEPR, and other
hypothalamic regions where LEPR expression has been associated with the regulation of food intake,
the animals showed a discrete reduction in body weight and adiposity due to an increase in energy
expenditure and also an improvement in the glucose and lipid metabolisms [38]. Interestingly, only
male mice showed decreased body weight and adiposity in that study, suggesting sex-dependant
changes in LEPR energy balance regulatory metabolism. Similar results were observed in another
study in which LEPR was overexpressed in all POMC neurones. In this study, mice reduced their body
weight by changing both food intake (decreased) and energy expenditure (increased); these animals
also showed lower plasma insulin and glucose levels [39]. In both studies, the improvement in glucose
levels and insulin sensitivity was independent of body weight, suggesting that leptin signalling
in POMC neurones has a role in regulating glucose homoeostasis and that this regulatory role is
not influenced by adiposity [37]. In fact, it has been described that leptin participates in regulating
glucose homeostasis and insulin sensitivity by signalling pathways, which include: Janus kinase (JAK),
phosphatidylinositol 3’-kinase (PI3K) and extracellular signal-regulated kinase (ERK) [40]. Therefore,
the association found in this study between rs11804091 and obesity in females may be related to a
lower expression of LEPR, which could derive in insulin resistance through mechanisms such as those
explained above; however, expression analyses should be performed to confirm this.
Leptin receptor plays an essential role in the physiological effects of leptin. Although some studies
have described very high circulating levels of leptin in carriers of LEPR mutations, others have not [15].
In the present study, we did not observe associations between LEPR variants and circulating leptin
levels, which suggests that SNPs in LEPR are not important regulators of circulating leptin levels.
As previously mentioned, the observed relationship between the SNP rs11804091 could be due to
an unknown functional variant flagged by it. Indeed, the functional association of an intronic SNP such
as rs11804091 with a disease may arise from different potential mechanisms such as altered miRNA
binding sites, or changes in TF-binding sites, either in the region of the characterized variant or in
that of a second SNP flagged by the first, or to a flagged missense variant that could have an impact
on the protein sequence and its functionality. The fact that we did not observe a high LD between
this SNP and the other analysed variants indicates that the functional SNP could be at any position
in the genome sequence, not necessarily near to the candidate gene. Similarly, we could not define a
functional role of rs11804091 affecting miRNA or TF binding sites, since the search of the available
databases did not retrieve significant findings.
Among the studied SNP in the present work, we demonstrated the association of five variants
(rs11208659, rs11804091, rs10157275, rs9436303 and rs1627238) with obesity in Spanish children and
adolescents, from which only the variant rs11208659 had been previously associated with severe
early-onset obesity in European children [13], and the rest of the associations are described for the first
time. We found no association between other previously described functional LEPR SNPs and obesity
such as rs1137101 (Gln223Arg), which has been associated with lower and higher obesity risk in Spanish
adults [16] and girls [29], respectively, but not in Turkish [24], Polish [25,30], Mexican Mestizo [26]
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or European [27] children and adolescents, as well as with type 2 diabetes [31]. Another variant, the
rs1137100 (Lys109Arg), has also been associated with obesity in European [27] and Indian [28], but
not in Mexican Mestizo [26], Spanish [29] or Danish [41] children. Finally, the SNP rs8179183 has been
associated with obesity in Mexican Mestizo [26] but not in Spanish [29], Polish [30] or European [27]
children. The results of these studies are inconclusive and controversial and may be due to the different
genetic background of the populations, as well as to the small sample sizes used.
Our study has several strengths and limitations, which should be mentioned. The main strengths
are the high quantity of analysed biomarkers and the strict SNPs’ selection method. The limitations
include a relatively small sample size for a genetic association study, which requires further validation
in independent and larger populations; and the fact that information on food intake and energy
expenditure, whose effects are regulated by leptin, was not available.
In conclusion, we demonstrate for the first time the gender-specific association between rs11804091
and obesity in Spanish girls. Our findings show that this polymorphism is also associated with insulin
resistance independently of obesity in girls, suggesting that it might have a potential effect or flag
a functional polymorphism that has an effect on the action of leptin on insulin metabolism. It will
be valuable to replicate these findings in larger populations to validate the results obtained in the
present study.
4. Materials and Methods
4.1. Study Design
In the present case-control multicentre study, 522 children were recruited, 286 classified as obese
(146 boys and 140 girls) and 236 as normal weight (133 boys and 103 girls) according to BMI, using
the sex- and age-specific cut-off points published by Cole et al. [42]. The children, aged 6–15 years,
were recruited in two Spanish cities (Cordoba and Santiago de Compostela) at primary care centres
and schools. Inclusion criteria were European-Caucasian heritage and absence of congenital metabolic
diseases. Exclusion criteria were non-European Caucasian heritage, the presence of congenital
metabolic diseases (e.g., diabetes or hyperlipidaemia), undernutrition, and the use of any medication
to control BP and glucose or lipid metabolism. There were no siblings included in the study. After
the initial assessment, parents of children that fulfilled the inclusion criteria were invited to take the
children to the paediatric unit of the participating hospitals for a clinical examination. The study aims
and procedures were fully explained to parents or guardians prior to written consent been taken, and
the children gave their assent.
This study was compliant with the Declaration of Helsinki 1975, revised in 2008, and followed the
recommendations of the Good Clinical Practice of the CEE (Document 111/3976/88 July 1990), and
the legally enforced Spanish regulation, which regulates the clinical investigation of human beings
(RD 223/04 about clinical trials). The Ethics Committee of the Reina Sofía University Hospital of
Cordoba, the Ethics Committee on Human Research of the University of Granada and the Bioethics
Committee of the University of Santiago de Compostela approved the study (Project identification
codes P06-CTS-2203 (04/05/2007) and PI 051968 (25/12/2005).
4.2. Anthropometric and Biochemical Measurements
The anthropometric measurements were taken with the children barefooted and in their
underwear. A standard beam balance was used to determine body weight (kg), a precision stadiometer
was used to measure height (cm) and for WC, with the child standing, an inelastic tape was applied
horizontally midway between the lowest rib margin and the iliac crest at the end of a gentle exhalation.
BMI was calculated and the z-BMI was obtained based on the Spanish references [43]. BP was measured
using a mercury sphygmomanometer with an appropriate cuff to the size of the child’s upper right
arm and following international recommendations [44]. Blood samples were taken after an overnight
fast and clinical biochemical analyses were performed at the laboratories of the participating hospital
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following internationally accepted quality control protocols. Insulin resistance was evaluated with the
HOMA-IR index [45].
4.3. Inflammation and Cardiovascular Risk Biomarkers
Inflammation and CVD risk biomarkers were measured on a Luminex® 200™ System (Luminex
Corporation, Austin, TX, USA), using three different LINCOplex™ kits of human monoclonal
antibodies (Linco Research, St Charles, MO, USA) as previously described [46]. Kit HADK1-61K-A
was used to determine adiponectin (CV: 7.9%) and active PAI-1 (aPAI-1) (CV: 6.6%). Kit HADK2-61K-B
was used for IL-6 (CV: 7.8%), IL-8 (CV: 7.9%), TNF-α (CV: 7.8%), and leptin (CV: 7.9%), while kit
HCVD1-67AK was used for sICAM-1 (CV: 7.9%), sE-selectin (CV: 11.2%), total PAI-1 (tPAI-1) (CV: 6.6%),
MPO (CV: 12.3%), and MMP-9 (CV: 6.8%). C-RP (CV: 4%) was determined using a particle-enhanced
turbidimetric immunoassay (Dade Behring Inc., Deerfield, IL, USA).
4.4. DNA Isolation and Genotyping
Twenty-eight SNPs in the LEPR gene were selected from the HapMap and NCBI databases among
those with a minor allele frequency (MAF) higher than 0.05 and a minimum pairwise LD of r2 = 0.8 for
the Caucasian population, as previously described [46,47]. The QIAamp Blood kit (Qiagen, Valencia,
CA, USA) was used to extract genomic DNA from peripheral white blood cells according to the
manufacturer’s instructions. Genotyping was performed on 96-well format Sentrix® arrays with the
Illumina GoldenGate Assay (Illumina Inc., San Diego, CA, USA).
The genotyping successful rate was >95% for all SNPs. We excluded variants rs4468199 and
rs3762274 from the study due to deviation from Hardy-Weinberg equilibrium in the normal-BMI group
(p < 0.05).
4.5. Statistical Analysis
All continuous variables were expressed as mean± standard error of the mean (SEM). Cholesterol,
insulin, HOMA-IR, MMP-9, and tPAI-1 were normalised using log-transformation. Comparisons
between normal-BMI and children with obesity variables were assessed using the Student’s t-test for
unpaired samples. The genotypic relative risk was assessed using logistic regression analysis under
an additive model with Bonferroni correction comparing the obese and the normal-BMI group in the
whole population and separately by sex. Linear or logistic regression analyses were performed to
estimate the association of each SNP with parameters linked to obesity and inflammation and CVD
risk biomarkers. Significance was considered at the level of p < 0.05. The statistical analyses were
performed with IBM-SPSS Statistics 20 (Armonk, NY, USA) and PLINK version 1.07 [48].
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/8/1690/s1.
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